Chinese biopharmaceutical company developing innovative small-molecule and biologic drugs, including therapies for fibrotic and inflammatory diseases.
Chinese biopharmaceutical company developing innovative small-molecule and biologic drugs, including therapies for fibrotic and inflammatory diseases.
Moat: narrow (IP / patents). Patent-protected pipeline of self-developed innovative drug candidates.
Headquarters: Suzhou, China · Employees: 1,055
Size Suzhou Zelgen Biopharmaceuticals (688266.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.13B, the 773rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥77.10 on 18 Nov 2026.
Performance Over six months the shares fell 24.7%, against +1.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 136.2% over the last twelve months (peer median +14.8%); the operating margin is 29.0% (peer median 11.1%).
Valuation It trades at 36.1× forward earnings against a peer median of 20.7× (6th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +98%, so the hurdle is -81 pp: the price already allows for a slowdown.
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.75B | CN¥804M | CN¥533M | CN¥386M | CN¥302M |
| Revenue growth | — | +51% | +38% | +28% | — |
| Gross profit | CN¥1.64B | CN¥682M | CN¥445M | CN¥302M | CN¥219M |
| EBITDA | n/a | -CN¥191M | -CN¥163M | -CN¥348M | -CN¥468M |
| Net income | CN¥569M | -CN¥163M | -CN¥138M | -CN¥279M | -CN¥457M |
| Free cash flow | CN¥829M | -CN¥201M | -CN¥42.6M | -CN¥283M | -CN¥452M |
| Capital expenditure | CN¥122M | CN¥181M | CN¥95.7M | CN¥62.6M | CN¥88.6M |
| Total debt | CN¥592M | CN¥1.15B | CN¥1.05B | CN¥886M | CN¥547M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals 688266.SS | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| InnoCare Pharma 9969.HK | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% |
| HUTCHMED (China) 0013.HK | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% |
| Ascentage Pharma Group International 6855.HK | $1.18B | -34% | +70% | -220% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688266.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.0% | -0.1% | lowest of 21 |
| 6-month return | -24.7% | +1.9% | 4th lowest of 21 |
| Distance from 52-week high | -51.8% | -19.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +136.2% | +14.8% | highest of 20 |
| Operating margin | 29.0% | 11.1% | 2nd highest of 19 |
| Forward P/E | 36.1× | 20.7× | 6th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 17.7% | -0.5% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +98.4% | +8.8% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -80.7 pp | -12.1 pp | 2nd least demanding of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |